Oncotelic Therapeutics, Inc. (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle nanoparticle platform. The research supports the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial for patients with advanced mTOR-sensitive solid tumors.
The publication details the platform’s formulation design, scalable cGMP manufacturing process, product stability, and preclinical performance. It demonstrates the potential of the Deciparticle platform to enable intravenous delivery of poorly water-soluble therapeutic compounds, which has been a significant challenge in drug development. The company stated that the research also supports broader applications for the platform beyond everolimus, including additional hydrophobic drug candidates.
Sapu003 is being evaluated in a Phase 1b dose-escalation study in combination with exemestane. The trial aims to assess safety, pharmacokinetics, and preliminary antitumor activity. This development is important because it could expand treatment options for patients with solid tumors that are sensitive to mTOR inhibition, particularly those who may not be candidates for oral everolimus due to absorption issues or other factors.
The Deciparticle platform could have implications for the broader pharmaceutical industry by providing a method to intravenously deliver drugs that have poor oral bioavailability or require high doses. This could improve the therapeutic index of existing drugs and enable the development of new drug candidates that were previously limited by solubility issues. For investors, the validation of this platform may signal potential value in Oncotelic’s pipeline and its joint ventures.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications. In addition to its own drug pipeline, Oncotelic benefits from the inventions of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. The company also licenses and co-develops drug candidates through joint ventures, including a 45% ownership of GMP Bio, which is advancing its own pipeline.
The company also develops PDAOAI, a proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI supports the platform and ongoing joint development work with TechForce Robotics, its strategic robotics and automation partner. For more information, visit www.oncotelic.com.
This publication represents a significant step in validating the Deciparticle platform and could accelerate the development of Sapu003 and other pipeline candidates. The ability to intravenously deliver hydrophobic drugs may address current limitations in cancer therapy and other therapeutic areas. The ongoing Phase 1b trial will provide further data on the safety and efficacy of Sapu003, which could lead to expanded treatment options for patients with advanced solid tumors. Investors and industry observers will be watching for updates from the trial and potential partnerships or licensing agreements that may arise from this validated platform.
